title: Worldwide experience with sugammadex sodium: implications for the United States.
abstract: Sugammadex sodium is a modified γ-cyclodextrin with a very high affinity for rocuronium and, to a lesser extent, vecuronium molecules. In vivo administration results in immediate encapsulation of rocuronium and vecuronium, resulting in termination of neuro- muscular blockade, usually within 3 minutes. This new neuromuscular blocking agent is specific for the aminosteroidal neuromuscular blocking agents rocuronium and vecuronium. Experience gained through worldwide clinical use of sugammadex offers US anesthesia providers the opportunity to better understand this new drug and its clinical applications. The seminal and current literature concerning clinical use of sugammadex is reviewed, and considerations for its incorporation into practice are provided.
authors.forename: Mark
authors.initials: M
authors.lastname: Welliver
authors.forename: Dennis
authors.initials: D
authors.lastname: Cheek
authors.forename: Juergen
authors.initials: J
authors.lastname: Osterbrink
authors.forename: John
authors.initials: J
authors.lastname: McDonough
mesh_terms: D000732:Androstanols / Q000819:agonists; D000769:Anesthesia, Inhalation; D000776:Anesthesiology / Q000379:methods*; D018685:Anesthetics, Inhalation; D004305:Dose-Response Relationship, Drug; D006801:Humans; D019148:Neuromuscular Blockade; D003473:Neuromuscular Nondepolarizing Agents / Q000819:agonists*; D017410:Practice Guidelines as Topic; D000077122:Sugammadex; D014481:United States; D014673:Vecuronium Bromide / Q000037:antagonists & inhibitors; D047408:gamma-Cyclodextrins / Q000008:administration & dosage*
chemical_list: D000732:Androstanols; D018685:Anesthetics, Inhalation; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D014673:Vecuronium Bromide